Remove Chemotherapy Remove Labelling Remove Mayo Clinic
article thumbnail

Understanding Recent Changes to 505(b)(2) Drugs and Reimbursement

Pharmacy Times

“This act…allowed a pathway for manufacturers to create a ‘copy’ of a licensed patent product to make it cheaper and more discounted,” Soefje, director of pharmacy cancer care services and associate professor of pharmacy at Mayo Clinic in Rochester, Minnesota, said at the HOPA conference.

article thumbnail

Pharmacists Take the Lead on Advanced Therapeutics

Pharmacy Times

Tichy, PharmD, MBA, vice chair of pharmacy formulary for Mayo Clinic, explained. 2 However, Dalton noted that some procedures can change once a treatment is FDA-approved, with complications from Risk Evaluation and Mitigation Strategy programs as well as the occasional surprise on an FDA label. Subscribe Now!

article thumbnail

ASH roundup: late breakers take the stage

pharmaphorum

At ASH, the E1910 clinical trial generated results could unlock a new patient population for Blincyto, after it was shown to improve overall survival in patients with no measurable residual disease (MRD) after induction chemotherapy for B-ALL. At the moment, Blincyto is approved to treat patients with MRD after induction treatment.